News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Biogen Idec, Inc. (Massachusetts) (BIIB) Release: The New England Journal of Medicine Publishes Pivotal Data Demonstrating Prophylactic Infusions Of ALPROLIX™ Effectively Controlled Bleeding In Hemophilia B Patients


12/5/2013 7:58:43 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass. & STOCKHOLM--(BUSINESS WIRE)--Today Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) announced the publication of detailed results from the pivotal Phase 3 study of ALPROLIXTM, the companies’ investigational long-lasting recombinant factor IX Fc fusion protein candidate for hemophilia B. The study appears in the Online First edition and will appear in the December 12 print issue of The New England Journal of Medicine (NEJM).

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES